\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Defence EDF NATO-EDADG DEFIS launched the call for tender this week for a Framework Contract (FwC) on a Business Accelerator and Matchmaking (BAMM) under the EU Defence Innovation Scheme (EUDIS). Please see EU Funding & Tenders Portal (europa.eu) for more information
The Business Accelerator aims to strengthen start-up and scale-up companies’ knowledge of defence end-users needs, and the companies’ business development and go-to-market capabilities. It will also help improve the companies’ access to financing, provide companies with a seed-financing voucher of EUR 65 000 per company and opportunities to meet with investors.
Additionally, matchmaking events will strengthen the companies’ networks and engagement with end-users, investors, and corporates. The first round of the EUDIS Business Accelerator batch will support 20 companies and is planned to be initiated in the end of 2024. The ambition is to increase the support to more companies in the coming years.
The EUDIS Matchmaking supports the implementation of the Defence Equity Facility (europa.eu). It will allow SMEs and small mid-caps’ business development in improving their access to financing, business partners and end-users. Companies joining EUDIS Matchmaking will have the opportunity to participate in matchmaking events across the EU and online, involving investors, governmental representatives, and corporates. EUDIS Matchmaking will establish an online platform to support the development of an innovation ecosystem and facilitate networking. EUDIS Matchmaking will also provide capacity building to investors to give them insights on defence market and technologies and provided tailored support to companies for pitching.
The deadline for submitting tenders for this call is 19 August 2024.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
